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Prevalence of metabolic syndrome among
HIV-positive and HIV-negative populations
in sub-Saharan Africa—a systematic review
and meta-analysis
Olamide O. Todowede1* , Solange Z. Mianda1 and Benn Sartorius1,2
Abstract
Background: Metabolic syndrome (MetS) is a constellation of conditions that increase the risk of cardiovascular
diseases. It is an emerging concern in sub-Saharan African (SSA) countries, particularly because of an increasingly
aging population and lifestyle changes. There is an increased risk of MetS and its components among people living
with Human immune deficiency syndrome (HIV) individuals; however, the prevalence of metabolic syndrome in the
SSA population and its differential contribution by HIV status is not yet established. This systematic review and
meta-analysis were conducted to estimate the pooled prevalence of metabolic syndrome in people living with HIV
and uninfected populations, its variation by sub-components.
Methods: We performed a comprehensive search on major databases—MEDLINE (PubMed), EBSCOhost, and
Cochrane Database of Systematic Reviews and Web of sciences for original epidemiological research articles that
compared proportions of the MetS and its subcomponents between people living with HIV and uninfected patients
and published between January 1990–December 2017. The inclusion criteria were adults aged ≥ 18 years, with
confirmed HIV status. We assessed the risk of bias using a prevalence studies tool, and random effect meta-analyses
were used to compute the pooled overall prevalence.
Results: A total of four cross-sectional studies comprising 496 HIV uninfected and 731 infected participants were
included in the meta-analysis. The overall prevalence of MetS among people living with HIV was 21.5% (95% CI 15.
09–26.86) versus uninfected 12.0% (95% CI 5.00–21.00%), with substantial heterogeneity. The reported relative risk
estimate for MetS among the two groups was twofold (RR 1.83, 95% CI 0.98–3.41), with an estimated predictive
interval of 0.15 to 22.43 and P = 0.055 higher for the infected population. Hypertension was the most prevalent
MetS sub-components, with diverse proportions of people living with HIV (5.2–50.0%) and uninfected (10.0–59.0%)
populations.
Conclusions: The high range of MetS prevalence in the HIV-infected population compared to the uninfected
population highlights the possible presence of HIV related drivers of MetS. Also, the reported high rate of MetS,
irrespective of HIV status, indicates a major metabolic disorder epidemic that requires urgent prevention and
management programs in SSA. Similarly, in the era of universal test and treat strategy among people living with
HIV cohorts, routine check-up of MetS sub-components is required in HIV management as biomarkers.
Systematic review registration: PROSPERO CRD42016045727
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Introduction
The problem of metabolic syndrome (MetS) has been
the main scourge of high mortality and morbidity [1].
Globally, the prevalence of metabolic syndrome (MetS)
is unknown [2], and country-specific prevalence varies
with estimated prevalences in excess of 25.0% in devel-
oped countries [3–5]. In sub-Saharan Africa (SSA), the
prevalence of metabolic syndrome is not well estab-
lished. The growing burden of the global metabolic dis-
order is occurring at a time when SSA is experiencing
an epidemiological transition, whereby the continent is
affected by the dual burden of infectious and non-com-
municable diseases [6]. Further, SSA remains the worst af-
fected region globally with over 25 million people living
with HIV [7]. The coexistence of infectious diseases and
non-communicable diseases is well documented in devel-
oped countries, and the intensity of this comorbidity is in-
comparable in SSA [8].
The global response to HIV has averted 30 million new
infections and nearly 8 million AIDS-related deaths, as a
result of antiretroviral therapy (ART) uptake [9]. This has
resulted in an aging population of people living with HIV,
living longer on ART and at greater risk of chronic dis-
eases and metabolic disorders [10, 11]. While the global
focus is on preventing and managing HIV infections, less
attention is on the metabolic impact of HIV infection and
treatment on infected individuals. The global pooled
prevalence of metabolic risk factors among people living
with HIV range from 16.7 to 31.3% [12].
Increased risk of MetS and its subcomponents among
people living with HIV individuals is well documented
and attributed to HIV infection, antiretroviral therapy,
and other related factors [13, 14]. Of which is similar to
the burden of MetS risk in the general population, as a re-
sult of associated modifiable risk factors [15, 16]. However,
little is known about the pooled prevalence of MetS and
the prevalence difference among people living with HIV
and uninfected population in SSA. Studies from developed
countries predominantly report MetS among HIV-positive
cohorts than in negative counterparts [15–17]. Studies
suggest that MetS outcomes are much lower among
people living with HIV compared to the general popula-
tion, but ART-treated patients have a higher risk of meta-
bolic complication [18]. Whether this risk is more or less
among people infected with HIV compared to uninfected
population remains controversial. This systematic review
and meta-analysis was conducted to understand the bur-
den of metabolic syndrome and its subcomponents among
people living with HIV and uninfected population in SSA.
Methods
Outcome of interest
The primary outcome of this study was to compare the
pooled prevalence of metabolic syndrome among people
living with HIV and uninfected populations in SSA. The
secondary aim was to compare metabolic syndrome
subcomponents (namely visceral obesity, hypertension,
diabetes, triglycerides, HDL cholesterol) among people
living with HIV and uninfected populations in SSA.
Protocol and registration
A study protocol (published) was developed prior to the
conduct of this review [19]. The protocol was registered
in the PROSPERO international prospective register of
systematic reviews (CRD42016045727). The protocol
was amended by removing the aspect of co-morbid diabetes
and hypertension components. The Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA)
guidelines were followed [20, 21].
Eligibility criteria
All studies (randomized control trials, cross-sectional,
case-control, and cohort studies) among adults (18+)
published from January 1990–December 2017 reporting
the prevalence of metabolic syndrome and its subcom-
ponents in people living with HIV and/or uninfected
populations were considered for inclusion. We excluded
studies that presented estimates from study participants
with unknown HIV status. The full inclusion and exclusion
criteria are presented in the aforementioned published
protocol [19].
Search strategy and selection process
MEDLINE (PubMed), EBSCOhost, and Cochrane Database
of Systematic Reviews and Web of sciences databases were
searched for papers published between January 1990 and
December 2017. The search terms used a combination of
relevant medical subject headings (MeSH) and database
specific terms with an African search filter. The search
strategy and the number of returned items are presented in
Appendix 1 and 2. The reference lists of identified articles
were traced through a web of science, and conference
proceedings checked using the International AIDS society
abstract archives. The titles of retrieved articles were exam-
ined to exclude ineligible articles. Given a large number of
Francophile countries in SSA, this review included eligible
studies published in French and were reviewed by a
French-speaking reviewer (SM). The selection of studies
was a multistep process with two reviewers (OO, SM)
independently screening the abstract and full text for
potential eligibility using the inclusion criteria, and dis-
crepancies were resolved through arbitration with a third
reviewer (BS). The flow diagram of the study selection and
exclusion process is presented in Fig. 1. The interrater
agreement for abstract and full-text screening was high at
90% and 100% respectively.
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Assessment of the methodological quality and risk of bias
of included studies
The methodological quality and risk of bias of selected
articles were assessed using the Effective Public Health
Practice Project/McMaster Evidence Review and Syn-
thesis Centre Tool: Quality Assessment Tool for Quan-
titative Studies [22], and the risk of bias tool for
prevalence studies [23]. A multistep process approach
was employed by two reviewers (OO, SM), and the
interrater agreement on quality and risk of bias were
80% and 90% respectively. A summary of the areas con-
sidered in the assessment of each domain is included in
Appendix 1 and 2—the risk of bias and quality assess-
ment of included studies.
Data item and collection process
Abstraction of meta-data from the included articles
was performed using a specifically designed Google
form, by two reviewers (OO and SM) independently.
Information extracted included publication details,
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Records Identified Through 
Database Searching
(n= 10,577 )
Additional Records Identified Through 
Other Sources 
(n = 0) 
Records After Duplicates Removed
(n = 125)
Abstract Records Screened
(n = 125) 
English =119 and 6 French studies 
Records Excluded 
(n = 31 ) 
• English= 30 and 1 French article 
• 30 Studies were on different 
population without HIV status 
• 1 Studies outcome was not 
defined
Full-text Articles Assessed for 
Eligibility (n = 94)
English = 89; French = 5 studies
Full-text Articles Excluded, With Reasons 
(n = 23) 
Studies Were Excluded Because of the 
• 11 studies were excluded because of 
the study outcome 
• 2 studies were excluded because of 
the participants were Africans in 
developed country.
• 1 was focused on children.
• 9 studies participants with unknown 
HIV status 
Studies Included in Data Extraction
(n = 71) 
English 66, French =4 
Studies Included in Qualitative 
Synthesis (Meta-Analysis) 
(n = 18)
n= 53 studies were excluded, with 
reasons,
• Studies were excluded because they 
were not presenting prevalence 
results for Metabolic syndrome but 
solely on other components  
Fig. 1 PRISMA flow diagram of study selection process
Todowede et al. Systematic Reviews             (2019) 8:4 Page 3 of 17
population sampled and sample size, metabolic preva-
lence estimates, participant’s characteristics, and HIV
status. Prevalence figures and 95% confidence intervals
(CIs) were extracted or calculated from the available
data using the Clopper-Pearson method [24]. Certain
authors were contacted for clarifications and/or further
data requests, and if contacted three times and no
response, the article concerned was removed from the
included studies.
Analysis
Data were analyzed using Stata 13.0 (StataCorp. 2013.
Stata Statistical Software: Release 13. College Station,
TX: StataCorp LP). Heterogeneity between study esti-
mates was assessed using the I2 statistic, i.e., the per-
centage of variation not due to sampling error across
studies. An I2 value above 50% indicates high hetero-
geneity. The meta-weighted prevalence (95% confidence
interval (CI)) of metabolic syndrome among HIV-positive
and HIV-negative populations was undertaken using a ran-
dom effects model (to account for heterogeneity). For the
studies with both HIV-positive and control HIV-negative
population, we estimated a meta-weighted relative risk
using a random effects approach. The influence of the esti-
mates for all included studies was assessed by the level of
risk of bias, quality of the study, study settings, and data
collection methods. The risk of bias and study quality
were classified as either low, moderate, or high, and we
performed the Egger test (in addition to funnel plot for
the HIV-positive only meta-analysis) to assess for potential
publication/small-study bias. The association between
HIV infection and MetS was estimated directly using the
“metan” function in STATA, where the default is RR, i.e.,
pooled risk ratio. We also check for influential outlying
studies using a random effects variance shift outlier model
(RVSOM) for detecting and accommodating outliers in a
meta-analysis [25].
In a meta-analysis of prevalence, when the estimate for
a given study tends towards either 0.0% or 100.0%, the
variance for that study moves towards zero, and as a
result, its relative weight may be overestimated [26]. Thus,
we transformed the prevalence estimates using the double
arcsine method to correct for this potential discontinuity
[26, 27]. For data analysis, we merged the estimates of
people living with HIV population by ATP III, IDF, JIS,
and WHO definitions criteria (average prevalence across
those with multiple definitions). The final pooled meta-es-
timates and 95% CIs were back-transformed for ease of
interpretation. We were unable to stratify prevalence
estimates by age, sex, and location with sufficient power,
due to the limited number of studies (four) that compared
estimates between HIV-negative and HIV-positive and
resultant sample sizes.
Results
Included studies search process
Our search returned a total of 10,577 publications, and
the titles were screened for eligibility and duplicates
were removed. A total of 125 articles were eligible for
abstracts screening. Based on the abstract screening,
94 articles were eligible for full-text screening and 31
articles were excluded. Among the 94 articles that were
reviewed full-text, 18 articles met the inclusion criteria,
contained or allowed the estimation of MetS preva-
lence estimates, and were selected for inclusion in this
review [28–45].
Characteristics of included studies
Study participation
The characteristics of the included studies are summa-
rized in Table 1. Of the 18 studies included in this re-
view, 4 studies [33, 35, 38, 40] compared the prevalence
of MetS among people living with HIV and uninfected
populations while the other 14 presented MetS preva-
lence estimates among people living with HIV subjects
only [28–32, 34, 36, 37, 39, 41–45].
Study breakdown from the three regions of sub-Sa-
haran Africa were as follows: West Africa, 11; South-
ern Africa, 3, and Eastern Africa, 4. By countries, the
distribution of studies were as follows: Nigeria, 3 [32,
33, 45]; Benin Republic, 2 [28, 44]; Burkina Faso, 2 [31,
43]; Cameroon, 2 [38, 40]; Ghana, 1 [41]; Ivory Coast, 1
[30]; South Africa, 3 [29, 35, 37]; Uganda, 1 [39]; and three
studies from Ethiopia [34, 36, 42]. Of the four studies that
presented estimates by HIV status, two were in Cameroon
and one was in Nigeria and South Africa respectively
Fig. 2.
Most of the studies (16 studies) were cross-sectionally
designed [28, 29, 31–34, 36–45], with one randomized
control trial and case-control study respectively [30, 35].
Most of the studies were hospital-based (16) with only
two that were community-based. More than half (10
studies) were published after 2015–2016, and two studies
were published in French [43, 44].
In the “Methods” section of the included studies, the
projected sample sizes were bigger than the actual
number of participants analyzed and reported. The
number of participants presented in the studies analysis
ranged between 50 to 300 HIV-negative participants
and 79 to 755 participants in people living with HIV.
About 25% of the total study participant’s samples were
men, and the age of participants ranged from 18 to 70
years. In the 12 studies with data on the duration of
ART, the duration ranged from 3 to 92 months.
The included studies applied various international cri-
teria to diagnose MetS. Six studies defined metabolic
syndrome using the International Diabetes Foundation
(IDF 2005) criteria, four studies used the Third Report
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Table 1 Characteristics of included studies
Author and publication
year
Study design, settings, and year Sex Mean age (years) Matched mean age (years) HIV status Hypertension definition criteria
used for MetS estimate
MetS definition
criteria
HIV+ HIV− HIV+ HIV−
1 Amusa et al., 2016 [33] Cross sectional, Nigeria, NS Both 41 ± 7/40 ± 8 α 41 ± 7 40 ± 8 150 50 Not stated Other
2 Ayodele et al., 2012 [32] Cross sectional, Nigeria, NS Both 39.5–9.3 NA NA 291 NA ≥ 130/85 and on antihypertensive
treatment
IDF, ATP, JIS
3 Berhane et al., 2012 [34] Cross-sectional, Ethiopia, 2010 Both 18 and above NA NA 313 NA ≥140/90 and on antihypertensive
treatment
ATP
4 Tesfaye et al., 2014 [42] Cross sectional, Ethiopia, 2012–13 Both 32.7 ± 9.7 (ART)
32.6 ± 7.8 (naïve)
NA NA 374 NA ≥ 130/85 and on antihypertensive
treatment
IDF, ATP
5 Sobieszczyk et al.,
2016 [29]
Cross-sectional, South Africa, 2013 Female Median 24 years NA NA 160 NA ≥ 130/85 and on antihypertensive
treatment
ATP
6 Obirikorang et al.,
2016 [41]
Cross sectional, Ghana,2013 Both 40.3 ± 0.8 NA NA 433 NA ≥ 130/85 and on antihypertensive
treatment
IDF, ATP, WHO
7 Ngatchou et al., 2013 [40] Cross sectional, Cameroon, 2009–10 Both 41 ± 12α/39 ± 10 39.0 ± 10.0 41 ± 12 108 96 ≥ 140/90 and on antihypertensive
treatment
IDF
8 Fourie et al., 2010 [35] Case control, South Africa, 2005 Both 44 ± 7.81α/44 ± 8.04 44.0 ± 8.04 44.0 ± 7.81 300 300 ≥ 130/85 and on antihypertensive
treatment
IDF, ATP
9 Muhammad et al.,
2013 [45]
Cross sectional, Nigeria, 2009 Both 32.5 ± 7.55 NA NA 200 NA ≥ 140/90 and on antihypertensive
treatment
IDF
10 Mbunkah et al.,
2014 [38]
Cross sectional, Cameroon, 2010–11 Both 18–70 41.1 ± 11.2 47.3 ± 13.7 173 50 ≥ 130/85 and on antihypertensive
treatment
ATP
11 Guehi et al., 2016 [30] Randomized control trial,
Ivory Coast, 2008–14
Both 29–42 NA NA 755 NA ≥ 140/90 and on antihypertensive
treatment
ATP
12 Mashinya et al.,
2015 [37]
Cross sectional, South Africa, 2013–14 Both 44.8 ± 11.8 NA NA 214 NA ≥ 140/90 and on antihypertensive
treatment
ATP
13 Guira et al., 2016 [31] Cross sectional, Burkina Faso, 2011 Both 44.8 + 7.4 NA NA 300 NA ≥ 130/85 and on antihypertensive
treatment
IDF
14 Hirigo et al., 2016 [36] Cross sectional, Ethiopia, 2013 Both 26.5–38 NA NA 185 NA ≥ 130/85 and on antihypertensive
treatment
IDF, ATP
15 Zannou et al., 2009 [28] Cohort, Benin, 2004–09 Both 38.0 ± 9.7 NA NA 79 NA ≥ 130/85 and on antihypertensive
treatment
IDF
16 Muyanja et al., 2016 [39] Cross sectional, Uganda, NS Both 30–43 NA NA 250 NA ≥ 140/90 and on antihypertensive
treatment
ATP
17 Adébayo et al., 2015 [44] Cross-sectional, Benin, NS Both 40,7 ± 9,71 NA NA 244 NA ≥130/85 and on antihypertensive
treatment
Other
18 Sawadogo et al.,
2005 [43]
Cross sectional, Burkina Faso, 2011 Both 41.4 ± 8.8 NA NA 400 NA ≥ 140/90 and on antihypertensive
treatment
IDF, ATP
NA not applicable, IDF International Diabetes Federation, ATP Adult Treatment Panel III report of the National Cholesterol Education Program, WHO World Health Organization, α HIV negative
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of the National Cholesterol Education Program and
Expert Panel on Detection, Evaluation and Treatment
of High Blood Cholesterol in Adults (Adult Treatment
Panel III) (NCEP/ATP III) criteria, while four studies
presented both NCEP/ATP III and IDF 2005 criteria.
One study employed the IDF 2005, NCEP/ATP III,
and JIS criteria and another with the IDF 2005, NCEP/
ATP III, and WHO criteria. Two of the included stud-
ies did not clearly specify the definition employed. The
included studies reported a variety of metabolic syn-
drome subcomponent [28, 30–40, 42–45] as described
in Table 2.
Risk of bias
A summary of the risk of bias of the included articles is
shown in Appendix 1 and 2. Sixteen studies (88%) were
considered to be at low risk of bias while the remaining
two studies were classified as medium risk of bias. None
of the studies was classified as high risk of bias. The major
risks of bias were the lack of presentation of the represen-
tativeness of the study sample in relation to the broader
target population (n = 8 studies, 44%) and the lack of
specification of a random selection of subjects (n = 11
studies, 61%).
Quality assessment
A summary of the quality assessment of the included
studies shows that half of the studies (n = 9, 50%) were
considered to be of low quality, six studies were consid-
ered to be of medium quality, and three studies were
considered to be of high quality. Most of the studies
were cross-sectional in design, and this was deemed the
weakest identified quality domain during our assess-
ment due to the associated temporality bias.
Outcome measurement
Prevalence The MetS prevalence estimates (Table 3)
for the included studies ranged from the highest
observed in south-western Uganda (145/250; 58.0%)
[39] to the lowest in Abidjan (47/755; 6.23%) among
people living with HIV populations [30]. Similarly, the
prevalence estimates among HIV-uninfected population
ranged from lowest in Nigeria (1/50; 2.0%) [33] to the
highest in South Africa (68/300; 22.6%) [35]. The
Fig. 2 Map of Africa indicating the regions where the included studies were situated
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prevalence rate of the sub-components varies by pres-
entation in the included studies (Table 4). Fourteen
(77.8%) and 3 (75.0%) studies reported hypertension
prevalence among people living with HIV and unin-
fected study participants respectively. Diabetes was re-
ported among the 4 (100.0%) HIV-uninfected focused
studies, while 15 (83.3%) infected population studies.
High triglycerides were reported in 12 (67.0%) studies
among infected population while 1 (25.0%) uninfected
population study. Visceral obesity prevalence was pre-
sented in 7 (39.0%) studies among infected cohorts, and
2 (50.0%) studies reported it among uninfected cohorts.
Similarly, 7 (39.0%) studies among the infected partici-
pants reported low HDL cholesterol as against 1 (25.0%)
study in the uninfected cohorts.
Sex variation Seven studies [28, 31, 32, 34, 36, 37, 39]
presented estimates of MetS stratified by sex among
people living with HIV subjects. The prevalence esti-
mates in males ranged from (6/95; 6.3%) [32] in Nigeria
to (41/81; 50.6%) [39] in Uganda using ATP III definition.
Similarly, the estimated prevalence using IDF defin-
ition among males ranged from (1/38; 3.1%) [28] in
Benin to (8/93;14.9%) [31] in Burkina Faso. Among
females, MetS estimate ranged from (9/38; 19.2% [28]
and 46/207; 85.1% [31]) to (15/171; 8.9% [37] and 104/
169; 61.5% [39]) using IDF and ATPIII definition
respectively.
Notable, MetS were shown to be consistently more
prevalent in female than male across the two criteria.
There is a relative estimate of 12.7% was among the
female against 3.6% using IDF criteria, and ATP III
definition estimated MetS prevalence at 19.7% among
females and 15.7% in males respectively. The sex vari-
ation in MetS prevalence among HIV-negative cohort
could not be ascertained because it was not reported.
Meta-weighted prevalence of MetS The meta-preva-
lence of MetS measured among people living with HIV
subjects irrespective of the MetS definition employed was
21.5% (95% CI 16.09–26.86%)—Fig. 3. The prevalence of
MetS among HIV-positive population measured by IDF
Table 2 Qualitative description of metabolic syndrome subcomponents prevalence within included studies
Author and publication year Metabolic syndrome subcomponent
HIV+ HIV−
1 Amusa et al., 2016 [33] Hypertension, diabetes, visceral obesity Hypertension, diabetes, visceral obesity
2 Ayodele et al., 2012 [32] Hypertension, diabetes, visceral obesity,
high triglyceride, low HDL cholesterol
–
3 Berhane et al., 2012 [34] Hypertension, diabetes, visceral obesity,
high triglyceride
–
4 Tesfaye et al., 2014 [42] Hypertension, diabetes, high triglyceride,
low HDL cholesterol
–
5 Sobieszczyk et al., 2016 [29] Diabetes, visceral obesity, high triglyceride,
low HDL cholesterol
–
6 Obirikorang et al., 2016 [41] – –
7 Ngatchou et al., 2013 [40] Diabetes Diabetes
8 Fourie et al., 2010 [35] Hypertension, diabetes, visceral obesity,
high triglyceride, low HDL cholesterol
Hypertension, diabetes, visceral obesity,
high triglyceride, low HDL cholesterol
9 Muhammad et al., 2013 [45] Hypertension, diabetes, low HDL cholesterol –
10 Mbunkah et al., 2014 [38] Hypertension –
11 Guehi et al., 2016 [30] Hypertension, diabetes, visceral obesity,
high triglyceride
–
12 Mashinya et al., 2015 [37] Hypertension, diabetes, high triglyceride,
low HDL cholesterol
–
13 Guira et al., 2016 [31] Hypertension, diabetes, high triglyceride,
low HDL cholesterol
–
14 Hirigo et al., 2016 [36] Hypertension, diabetes –
15 Zannou et al., 2009 [28] Hypertension, diabetes, visceral obesity,
high triglyceride
–
16 Muyanja et al., 2016 [39] Hypertension, high triglyceride,
low HDL cholesterol
–
17 Adébayo et al., 2015 [44] Hypertension, diabetes, high triglyceride Hypertension, diabetes, visceral obesity
18 Sawadogo et al., 2005 [43] Diabetes –
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was higher than those measured by the ATP III definition
at 25.7% (95% CI 16.62–34.79%) versus 19.9% (95% CI
12.26–27.45). Similarly, the meta-prevalence of the MetS
in HIV-negative subjects in this review was 12.0% (95% CI
5–21%). The overall relative risk of MetS prevalence
among people living with HIV population compared with
HIV-uninfected population was 1.83 (95% CI 0.99–3.41),
with an estimated predictive interval of (0.15 to 22.43)
P value = 0.055—Fig. 4.
Publication bias A funnel plot assessing the pooled
prevalence of metabolic syndrome among people living
with HIV populations suggested a weak publication bias
among the included studies. Egger test results (P =
0.271) did not indicate significant small study effect
bias when considering HIV-positive studies. Also, a
random effects variance shift outlier model analysis
suggested that the Muyanja et al. [39] study was a
prominent and influential outlier in our study. Thus,
further meta-regression analysis to identify the source
of heterogeneity was performed and also suggests that
risk of bias score and year were potential sources of
heterogeneity. However, a meta-regression model in-
cluding year and risk of bias score and excluding the
aforementioned influential outlier study only reduced the
adjusted I2 to ~ 65%. Hence, there was still a large residual
heterogeneity which is a potential limitation of the under-
lying data.
Discussion
MetS prevalence overview
To our knowledge, this is the first systematic review
and meta-analysis of the MetS prevalence in the
sub-Saharan African population by HIV status. Notably,
the total prevalence of MetS among people living with
HIV population was significantly higher at 21.5% (95%
CI 15.09 to 26.86) with estimated predictive interval of
(0.02 to 0.52) irrespective of the definition criteria com-
pared with their HIV-negative counterparts at 12.0%
(95% CI 5–21%). However, the wide prevalence range
indicates substantial heterogeneities and this is as a result
of influential outlying estimates from one of the included
study.
Table 3 Prevalence of MetS by definition
Author and publication year HIV status Prevalence by definition criteria
HIV+ HIV− IDF ATP Others
1 Amusa et al., 2016 [33] 150 50 NA NA 41 (27.3%), P < 0.01Ϯ
2 (4%), P < 0.01α—not stated
2 Ayodele et al., 2012 [32] 291 NA 50 (17.2%) 37 (12.7%) 61(21.0%)—JIS
3 Berhane et al., 2012 [34] 313 NA NA 66 (21.1%) NA
4 Tesfaye et al., 2014 [42] 374 NA 23.8% 16.8% NA
5 Sobieszczyk et al., 2016 [29] 160 NA NA 27 (8.7%) NA
6 Obirikorang et al., 2016 [41] 433 NA 183 (42.3%) 209 (48.3%) 106 (24.5%)—WHO
7 Ngatchou et al., 2013 [40] 108 96 47.0%, P = 0.02Ϯ
21.0%, P = 0.02α
NA NA
8 Fourie et al., 2010 [35] 300 300 21.1%, P = 0.65Ϯ
22.6%, P = 0.65α
15.2% P = 0.18Ϯ
11.5% P = 0.18α
NA
9 Muhammad et al., 2013 [45] 200 NA ART = 21.0%;
Naive = 9.0%
P = 0.017
NA NA
10 Mbunkah et al., 2014 [38] 173 50 NA 15.6% (27/173) (P = 0.020)Ϯ
8.0% (4/50)α
NA
11 Guehi et al., 2016 [30] 755 NA NA 47 (6.2%) P > 0.0001 NA
12 Mashinya et al., 2015 [37] 214 NA NA 20 (9.6%) P = 0.56 NA
13 Guira et al., 2016 [31] 300 NA 54 (18.0%) NA NA
14 Hirigo et al., 2016 [36] 185 NA 24.3% (45/185) 17.8% NA
15 Zannou et al., 2009 [28] 79 NA 10 (12.7%) NA NA
16 Muyanja et al., 2016 [39] 250 NA NA 145/250 (58.0%) P value = 0.10 NA
,NA not applicable
αHIV-negative
ϮHIV-positive
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Table 4 Qualitative description of metabolic syndrome subcomponents prevalence within included studies
Author and
publication year
Hypertension Diabetes Visceral obesity High triglycerides Low HDL cholesterol
HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV−
1 Amusa et al.,
2016 [33]
46.0%
P < 0.01
5/50 (10.0%)
P < 0.01
42/150 (28.0%)
P < 0.01
2/50 (4.0%)
P < 0.01
48/150 (32.0%)
P 0.79
15/50 (30%)
P 0.79 (P = 0.79)
NP NP NP NP
2 Ayodele et al.,
2012 [32]
82 (28.2%),
P = 0.146
NP 54 (18.6%)
P = 0.600
NP 56 (19.2%)
P < 0.001
NP 38 (13.1%)
P = 0.880
NP 159 (54.6) P = 0.013 NP
3 Berhane et al.,
2012 [34]
110/313
(35.1%)
NP 78/313 (24.9%) 43/313 (13.7%) 83/31 (26.5%) NP
4 Tesfaye et al.,
2014 [42]
SBP = 39/
374
DBP = 33/
374
NP 103 NP NP NP 154 NP 248 NP
5 Sobieszczyk et al.,
2016 [29]
NP NP (0.7 to 1.9%)
P = 0.346
33.5 to 44.3%
(P = 0.060)
9.4 to 13.3%,
P = 0.112
56.6 to 61.0%,
P = 0.283
6 Obirikorang et al.,
2016 [41]
NP NP NP NP NP NP NP NP NP NP
7 Ngatchou et al.,
2013 [40]
NP NP 26%
P < 0.01
1%
P < 0.01
NP NP NP NP NP NP
8 Fourie et al.,
2010 [35]
50.0%
P = 0.03
59.0%
P = 0.03
ATP III
22.7% P = 0.49
IDF
36.6% P = 0.08
ATP III
25.1%
P = 0.49
IDF
43.7%
P = 0.08
ATP III
Male—0.9%
P = 0.32
Female—18.3%
P = 0.93
IDF
Male—2.6%
P = 0.31
Female—33.9%
P - 0.22 (P = 0.22)
ATP III
Male—0.0%
P - 0.32 (P = 0.32)
Female—18.7% P - 0.93
(P = 0.93)
IDF
Male—0.9%
P - 0.31 (P = 0.31)
Female—40.1% P - 0.22
(P = 0.22)
ATP III
18.2% P = 0.19
IDF
14.3% P = 0.19
ATP III
17.6%
P = 0.28
IDF
14.3%
P = 0.28
ATP III
Male—47.4%,
Female—62.6%
P < 0.0001
IDF
Male—46.5%
P < 0.0001
Female—62.6%
P < 0.0001
ATP III
Male—12.1%
P < 0.0001
Female—33.7%
P < 0.0001
IDF
Male—11.2%
P < 0.0001
Female—33.7%
P < 0.0001
9 Muhammad et al.,
2013 [45]
9.5
(P < 0.001).
NP 3 (P = 1.0) NP NP NP 16 68.5%
10 Mbunkah et al.,
2014 [38]
24.7% NP NP NP NP NP NP NP NP NP
11 Guehi et al.,
2016 [30]
37 (4.9%) NP 4 (0.5%) NP 128 (17.0%) NP 128 (17.0%) NP NP NP
12 Mashinya et al.,
2015 [37]
56 (26.2%) NP 10 (4.7%) NP NP NP Male = 35.0 vs
female = 12.5%,
P = 0.001)
91 (43.8%)
13 Guira et al.,
2016 [31]
36 (66.7%) NP 16 (29.6%) 27 (50%) 37 (68.5%)
14 Hirigo et al.,
2016 [36]
18/185
P = 0.84
NP IDF criteria
58 (31.3%)
NP NP NP NP NP NP NP
15 Zannou et al.,
2009 [28]
29 (42.6) 6 (7.6%) 24 (33.3%) NP 10 (14.1%) NP NP NP
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Table 4 Qualitative description of metabolic syndrome subcomponents prevalence within included studies (Continued)
Author and
publication year
Hypertension Diabetes Visceral obesity High triglycerides Low HDL cholesterol
HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV−
16 Muyanja et al.,
2016 [39]
13 (5.2%)
P = 0.46
NP NP NP NP NP 74 (29.6%) 0.76 NP 214 (85.6%) 0.16 NP
17 Adébayo et al.,
2015 [44]*
60 (24.6%) 5 (10%),
P < 0.01
5 (2.04%) 2 (4.0%) NP NP 44 (18.0%)
Male—12 (12.6%)
Female—26
(13.3%)
NP NP NP
18 Sawadogo et al.,
2005 [43]*
NP NP 1.3%, CI
(0.5–3.0)
NP NP NP NP NP NP NP
*French publication
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As mentioned above this review suggests a twofold
higher risk of MetS (RR 1.83, 95% CI 0.98–3.41), with an
estimated predictive interval of (0.15 to 22.43) P value =
0.055 among people living with HIV subjects compared
to their HIV-negative counterparts, and this ratio was
not statistically significant. This finding suggests HIV
infection and ART appear to contribute to a significant
excess burden of MetS over and above the contribution
of traditional lifestyle-related risk factors. The findings
of this review are somewhat related to ones discussed
in other studies [46–48]. The meta-prevalence of MetS
among people living with HIV populations in SSA
countries has shown to be higher when compared to
reported estimates from developed countries [18, 49].
.       (0.02, 0.52)with estimated predictive interval
Overall  (I^2 = 96.24%, p = 0.00)
Sobieszczyk et al 2016
Mashinya et al, 2015
Ayodele et al 2012
Tesfaye et al, 2014
Fourie et al, 2010
Muyanja et al 2016
Obirikorang et al 2016
Berhane et al 2012
Zannou et al 2009
Mbunkah et al, 2014
Sawadogo et al,  2005
Muhammad et al, 2013
Study
Guira et al, 2016
Hirigo et al, 2016
Ngatchou et al 2013
Guehi et al, 2016
Adebayo et al, 2015
Amusa  et al, 2016
0.21 (0.15, 0.27)
0.19 (0.14, 0.26)
0.09 (0.06, 0.14)
0.17 (0.13, 0.22)
0.20 (0.16, 0.25)
0.18 (0.14, 0.23)
0.58 (0.52, 0.64)
0.38 (0.34, 0.43)
0.21 (0.17, 0.26)
0.13 (0.06, 0.22)
0.16 (0.11, 0.22)
0.11 (0.08, 0.15)
0.15 (0.10, 0.21)
ES (95% CI)
0.18 (0.14, 0.23)
0.21 (0.15, 0.28)
0.44 (0.34, 0.53)
0.06 (0.05, 0.08)
0.18 (0.14, 0.24)
0.27 (0.20, 0.35)
100.00
5.47
5.56
5.63
5.67
5.63
5.59
5.69
5.64
5.15
5.50
5.68
5.54
Weight
5.63
5.52
5.31
5.75
5.59
5.45
%
0 .1 .25 .5 .75 1
Fig. 3 Forest plot of the prevalence of metabolic syndrome in studies on HIV-positive subjects
Fig. 4 Forest plot of the prevalence ratios of metabolic syndrome comparing HIV-positive to HIV-negative subjects
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Similarly, the estimate of MetS among the uninfected
population in this review is similar to the AGEhIV co-
hort study in the Netherlands, underpinning the signifi-
cance of excess MetS risk among people living with HIV
compared to HIV-negative [50]. Irrespective of the risk
differences of MetS among people living with HIV and
uninfected patients in this review not being significant,
it is notable that the prevalence of MetS in both co-
horts are high and ranged within the earmarked global
burden. This implies that the burden of MetS is grow-
ing vehemently in SSA with or without HIV; hence, other
related factors such as lifestyles, diets, aging, and other
interlinked factors require crucial prevention and manage-
ment beyond HIV.
Across the major criteria (ATP 2001, IDF 2005, JIS) used
by most studies included in this review, the estimated MetS
prevalence was highest based on the IDF 2005 definition
(25.7%). This was different from a similar review that found
higher estimates based on the ATP definition criteria [12].
This implies a large waist circumference band among the
infected cohorts included in this review, especially females,
as this is a compulsory requirement using IDF definition.
This agrees with the finding underlining high adiposity
(based on body mass index) and waist circumference
among people living with HIV subjects [18, 51]. Further
research is needed to understand the difference between
waist circumferences by HIV status, as this was not estab-
lished in this review.
The analysis of the meta-prevalence of MetS individual
subcomponents was limited given the lack of adequate
reporting in the included studies. Diabetes and hyperten-
sion were the most reported sub-components, but among
people living with HIV cohorts. Nonetheless, studies have
described the outcome of the high prevalence of hyperten-
sion and diabetes among people living with HIV popula-
tions [52, 53]. Further research is required to understand
which of the sub-component is the most prevalent and
contributes to the development of MetS by HIV status.
With the widespread ART uptake and the introduction
of treat, all strategy irrespective of viral load and CD4
count, we anticipated an increase in the burden of MetS
irrespective of age and sex in SSA. Despite an unbalance
representation of people living with HIV studies against
uninfected groups in this review, the prevalence of MetS
was essentially higher among the infected population.
The absence of study conducted specifically on populations
with confirmed negative HIV status might have accounted
to these findings. Otherwise, it may be the true reflection
of the ubiquitous MetS burden in sub-Saharan Africa irre-
spective of HIV status, as a result of improved life expect-
ancy, globalization, and lifestyles. Thus, a scale-up in the
awareness, prevention, and management of metabolic
disorder is directly needed in this continent, to curb
the emerging epidemic.
Strengths and limitations
Strengths
This review strictly adhered to the PRISMA guidelines
to maximize the robustness and rigor of the employed
methodology. We also conducted a very rigorous quality
and risk of bias assessment. To our knowledge, this is
the first systematic review to attempt to compare the
burden of MetS by HIV status. Furthermore, we did not
exclude French-based studies given the region of focus
in this review and a large number of Francophile coun-
tries with HIV burden.
Limitations
Our findings may not be generalizable to all people living
with HIV and uninfected individuals given the small number
of included studies and potential non-representativeness.
Given the varied methodological designs of the studies in-
cluded in the review, the calculation of the pooled preva-
lence estimate may have been affected by this heterogeneity,
as suggested by the very high I2 statistic of 96.05% based on
the final eligible pool of studies included in this meta-ana-
lysis. Some of the included study’s authors were contacted
for raw data and further clarifications; however, some esti-
mates had to be calculated from data provided in the article.
One of the included studies among people living with HIV
cohort was a randomized control trial study, but we do not
suspect that the inclusion and exclusion criteria of the trial
participants would introduce substantial bias to our study,
as these are not related to the metabolic risk factors/condi-
tions we are attempting to assess among adults living with
HIV. The pooled risk ratio of the burden of metabolic syn-
drome among HIV-infected population compared to their
negative counterparts should be interpreted with caution
given that only 4 out of 18 studies compared MetS by HIV
status. Furthermore, limited comparison of pooled preva-
lence of MetS combining all 18 studies versus meta-estimate
among combined HIV-negative subjects in the 4 studies
(and relatively small pooled sample size of HIV-negative
subjects) can be done as the underlying epidemic profile var-
ies tremendously across the region. A further limitation was
the lack of standardized MetS definition employed across
the various study settings.
Another limitation of this review was the limited sub-
group stratification of MetS burden by sex and ART
regimen among the eligible studies. However, the associ-
ation of antiretroviral therapy with MetS has been previ-
ously documented [12, 54]. Also, the relationship
between the use of ART and naïve with MetS prevalence
could not be ascertained in this review, as 16 out of 18
studies on HIV-infected subjects reported that the par-
ticipants were ART-experienced. This may explain the
high prevalence of MetS quantified in this review. It is
thus important to include routine and regular metabolic
disorder check in the routine follow-ups of people living
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with HIV to optimize prevention and management, es-
pecially in the era of treat-all.
Thus, further research is required in estimating the ex-
tent and association of HIV status and metabolic syndrome
and/or its subcomponents within SSA. Moreover, a more
standardized approach of classifying MetS in SSA should
be adopted to allow better comparability across countries
in the region and whether conventional waist circumfer-
ence cutoffs are appropriate in the Africa context.
Conclusion and implications
MetS prevalence in people living with HIV and unin-
fected individuals is high in sub-Saharan Africa; how-
ever, based on our findings, this appears to be a non-
significant high prevalence comparing HIV-positive
and HIV-negative group. However, this review needs
to be interpreted with caution given the weaknesses
alluded to above. More primary research is required in
SSA to give a better understanding of the difference in
the burden of metabolic syndrome in the context of
high HIV burden. However, the findings of this review
have implications for public health practice and pol-
icymakers within SSA as HIV-positive individual’s life
expectancy increases in the post ART rollout era and
also in the context of an unfolding epidemiological
transition where an increasing burden of non-commu-
nicable in the context of a high dual and persistent
burden of infectious disease. Implementing an inclu-
sive/integrated care plan for people living with HIV
populations in the region is essential. This implies the
increased presence of other healthcare needs beyond
HIV and other communicable infection that might
overburden our already overstrained healthcare sys-
tems. Early screening of metabolic syndrome subcom-
ponents irrespective of HIV status to reduce future
metabolic syndrome epidemic cost is important in the
era of increased population aging and obesity, and this
has been observed in SSA.
Appendix 1
Table 5 Search strategy with MeSH terms
Search Search terms Number of hits
PubMed
Number of hits
Ebscohost
Number of hits
Cochrane
Database
Number of hits
Web of
Science
#1 metabolic syndrome OR syndrome X OR insulin resistance
syndrome
187,904 27,587 10,928 128,787
#2 Hypertension OR high blood pressure 533723 102,771 89,556 107.083
#3 Type 2 diabetes mellitus OR type 2 diabetes OR diabetes
Mellitus OR non-insulin dependent diabetes OR adult
onset diabetes
435357 92,546 38,353 377,811
#4 Human Immunodeficiency Virus OR Acquired Immune
Deficiency Syndrome Virus OR AIDS Virus OR HIV
Seronegativities OR Seronegativity, HIV OR HIV
Seropositivities OR Seropositivity, HIV
329085 139,326 8285 268,598
#5 #1 OR #2 OR #3 AND #4 8693 137,326 97,517 134,466
#6 African filter((((Angola OR Benin OR Botswana OR “Burkina Faso”
OR Burundi OR Cameroon OR “Cape Verde” OR “Central African
Republic” OR Chad OR Comoros OR Congo OR “Democratic Republic
of Congo” OR Djibouti OR “Equatorial Guinea” OR Eritrea OR Ethiopia
OR Gabon OR Gambia OR Ghana OR Guinea OR “Guinea Bissau” OR
“Ivory Coast” OR “Cote d’Ivoire” OR Kenya OR Lesotho OR Liberia OR
Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR
Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR
Reunion OR Rwanda OR “Sao Tome” OR Senegal OR Seychelles
OR “Sierra Leone” OR Somalia OR “South Africa” OR Sudan OR
Swaziland OR Tanzania OR Togo OR Uganda OR “Western Sahara”
OR Zambia OR Zimbabwe OR “Central Africa” OR “Central African”
OR “West Africa” OR “West African” OR “Western Africa” OR “Western
African” OR “East Africa” OR “East African” OR “Eastern Africa” OR
“Eastern African” OR “South African” OR “Southern Africa” OR
“Southern African” OR “sub Saharan Africa” OR “sub Saharan African”
OR “sub Saharan Africa” OR “sub Saharan African” NOT “guinea pig”
NOT “guinea pigs” NOT “aspergillus niger” ))))
310426 354,204 15,628 467,826
#7 # 5 AND # 6 Limits: 01/01/1990 to 28/02/2017 in English and
French on humans
632 7960 1825 160
Total = 125 Title screening 98 25 0 2
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Appendix 2
Table 6 Presentation of the risk of bias of included studies
S/
N
Author (s)
and year of
publication
Was the study’s target
population a close
representation of the
national population in
relation to relevant
variables, e.g. age, sex,
occupation?
Was the
sampling frame
a true or close
representation
of the target
population?
Was some form
of random
selection used to
select the sample,
OR, was a census
undertaken?
Was the
likelihood
of non-
response
bias
minimal?
Were data
collected
directly from
the subjects
(as opposed
to a proxy)?
Was an
acceptable
case
definition
used in the
study?
Was the study instrument
that measured the parameter
of interest (e.g. prevalence of
low back pain) shown to
have reliability and validity (if
necessary)?
Was the
same
mode of
data
collection
used for all
subjects?
Were the
numerator(s)
and
denominator
r(s) for the
parameter of
interest
appropriate
Summary
on the
overall
risk of
study bias
1 Adébayo
et al., 2015
[44]
No (high risk) No (high risk) No (high risk) No (high
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Moderate
risk (4–6)
2 Amusa
et al., 2016
[33]
Yes (low risk) No (high risk) No (high risk) No (high
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Moderate
risk (4–6)
3 Ayodele
et al., 2012
[32]
Yes (low risk) Yes (low risk) No (high risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
4 Berhane
et al., 2012
[34]
Yes (low risk) Yes (low risk) No (high risk) No (high
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
5 Fourie et al.,
2010 [35]
Yes (low risk) Yes (low risk) Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
6 Guehi et al.,
2016 [30]
Yes (low risk) Yes (low risk) Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
7 Guira et al.,
2016 [31]
No (high risk) No (high risk) No (high risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
8 Hirigo et al.,
2016 [36]
No (high risk) No (high risk) No (high risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
9 Mashinya
et al., 2015
[37]
No (high risk) Yes (low risk) No (high risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
10 Mbunkah
et al., 2014
[38]
No (high risk) Yes (low risk) Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
11 Muhammad
et al., 2013
[45]
Yes (low risk) Yes (low risk) Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
12 Muyanja
et al., 2016
[39]
No (high risk) No (high risk) No (high risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
13 Ngatchou
et al., 2013
[40]
Yes (low risk) Yes (low risk) No (high risk) No (high
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
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Table 6 Presentation of the risk of bias of included studies (Continued)
S/
N
Author (s)
and year of
publication
Was the study’s target
population a close
representation of the
national population in
relation to relevant
variables, e.g. age, sex,
occupation?
Was the
sampling frame
a true or close
representation
of the target
population?
Was some form
of random
selection used to
select the sample,
OR, was a census
undertaken?
Was the
likelihood
of non-
response
bias
minimal?
Were data
collected
directly from
the subjects
(as opposed
to a proxy)?
Was an
acceptable
case
definition
used in the
study?
Was the study instrument
that measured the parameter
of interest (e.g. prevalence of
low back pain) shown to
have reliability and validity (if
necessary)?
Was the
same
mode of
data
collection
used for all
subjects?
Were the
numerator(s)
and
denominator
r(s) for the
parameter of
interest
appropriate
Summary
on the
overall
risk of
study bias
14 Obirikorang
et al. 2016
[41]
Yes (low risk) Yes (low risk) No (high risk) No (high
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
15 Sawadogo
et al., 2005
[43]
Yes (Low risk) Yes (low risk) Yes (low risk) No (high
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
16 Sobieszczyk
et al., 2016
[29]
Yes (low risk) Yes (low risk) No (high risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
17 Tesfaye
et al., 2014
[42]
No (high risk) Yes (low risk) Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
No (high risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
18 Zannou
et al., 2009
[28]
No (high risk) Yes (low risk) Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Yes (low
risk)
Yes (low risk) Low risk
(0–3)
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